Haematologica · 2007 · 38 citations · 7 references
MedicineHematologyOncologyBone MetabolismHematologic OncologyHematopathologyBone Marrow EvaluationBone Marrow PathologyBone PathologyBone TumorsMetastatic Bone DiseaseMultiple MyelomaBone Marrow AssessmentMultiple Myeloma Of BoneMyeloma Bone DiseaseMyeloma PathogenesisPrognostic Staging SystemsRankl-opg Signaling Axis
Serum levels of OPG and RANKL and their clinical correlations were analyzed in 66 newly-diagnosed patients with multiple myeloma (MM). RANKL and RANKL /OPG ratio were significantly increased in advanced clinical stages and high grade myeloma bone disease (MBD), while OPG showed a tendency to decrease. Renal failure modified the expression of OPG. RANKL and RANKL/OPG ratios are informative markers for myeloma tumor burden and MBD.
7
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
Therese Standal, Carina Seidel, Øyvind Hjertner et al. · Blood · 2002 · 243 citations · Full text
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease
Carina Seidel, Øyvind Hjertner, Niels Abildgaard et al. · Blood · 2001 · 173 citations · Full text
Ulrike Heider, Corinna Langelotz, Christian Jakob et al. · PubMed · 2003 · 157 citations
Serum osteoprotegerin levels in healthy controls and cancer patients.
Allan Lipton, Suhail M. Ali, Kim Leitzel et al. · PubMed · 2002 · 133 citations